by paul | Dec 5, 2023 | Blog, Uncategorized
The Phase III clinical trial is now underway to evaluate fatty acid synthase (FASN) inhibitor ASC40 (Denifanstat) from Ascletis Pharma, Inc. for treatment of moderate to severe acne vulgaris.The randomized, double-blind, placebo-controlled, multicenter clinical trial...
by paul | Nov 1, 2023 | Blog
The FDA has approved Cosentyx® (secukinumab) from Novartis to treat moderate to severe hidradenitis suppurativa (HS) in adults. It is approved as a 300mg dose, administered every four weeks, with the option to increase to every two weeks if the patient has an...
